Navigation Links
Cadence Pharmaceuticals Submits Acetavance New Drug Application for the Treatment of Acute Pain and Fever
Date:5/14/2009

pany to perform additional non-clinical or clinical studies; the potential that the FDA may impose other requirements to be completed before or after regulatory approval; the company's reliance on third parties to assist with its clinical trials, regulatory submissions, manufacturing and other important aspects of the Acetavance development program, and the risk that regulatory approval may be delayed if their performance is found to have been substandard; risks associated with FDA heightened scrutiny over the new drug approval process and the potential for accidental and intentional overdoses of acetaminophen, primarily in the outpatient setting; intense competition from existing and new products, which could diminish the commercial potential for Acetavance; the possibility that the patent rights covering Acetavance, which are limited to a specific intravenous formulation of acetaminophen and do not cover the active ingredient, may not be sufficient to preclude other formulations of intravenous acetaminophen from being developed by competitors; the potential that Cadence may require substantial additional funding in order to obtain regulatory approval of Acetavance and, if approved, to successfully launch this product candidate, and that the company may not be able to raise sufficient capital when needed, or at all; and other risks detailed in Cadence's prior press releases as well as in Cadence's periodic public filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Cadence undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

Cadence(TM) and A
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
2. Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
4. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
5. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
6. Ferring Pharmaceuticals Unveils Six-Month Efficacy Data for EUFLEXXA(R) for the Treatment of Osteoarthritis Knee Pain
7. Addrenex Pharmaceuticals Expands Product Pipeline by Licensing New Drug to Treat Narcolepsy
8. BioCryst Pharmaceuticals to Announce Peramivir Update and First Quarter 2009 Financial Results on May 8, 2009
9. ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the Association for Research in Vision and Ophthalmology (ARVO) 2009 Annual Meeting
10. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
11. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  A novel wearable injector slightly larger than an Oreo ... to self-inject prescription drugs in the large doses required to ... autoimmune deficiencies, and genetic disorders.  An emerging ... 2018, according to analysts.   Many of these drugs will require ...
(Date:1/14/2014)... (Nasdaq: LMNX ) today announced that it expects ... Monday, February 3, 2014. A press release announcing the results ... (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) Management will ... financial results for the fourth quarter and twelve months ended ...
(Date:1/14/2014)... Calif. , Jan. 14, 2014 The Brandeis Medical Center, ... Angeles a premier and affordable laser tattoo removal experience ... Dr. Brandeis, focus is in providing high quality cosmetic services with ... patients. " Southern California has seen ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... -,Phytopharm plc (LSE: PYM) ("Phytopharm" or the ... reverses the,changes in the area of the ... be presented by Dr Jonathan Brotchie, an,internationally ... International Congress of Parkinson's Disease and Movement,Disorders' ...
... UVIDEM was well-tolerated with signs of durable,disease control ... 05, 2007 /PRNewswire-FirstCall/ -- IDM,Pharma, Inc. today presented ... vaccine clinical trial (DC-MEL-202). The,results showed that UVIDEM ... of immune response in patients with,progressive metastatic melanoma. ...
Cached Medicine Technology:Cogane Data Presented at ‘11th International Congress of,Parkinson’s Disease and Disorders’ 2Cogane Data Presented at ‘11th International Congress of,Parkinson’s Disease and Disorders’ 3Cogane Data Presented at ‘11th International Congress of,Parkinson’s Disease and Disorders’ 4Cogane Data Presented at ‘11th International Congress of,Parkinson’s Disease and Disorders’ 5IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 2IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 3IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 4IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 5
(Date:4/18/2014)... The Gerontologist reports that among ... a decrease in anxiety about death and increases in ... lives. In particular, listening to gospel music is associated ... increase in sense of control. , These associations are ... individuals of both low- and high-socioeconomic status. , The ...
(Date:4/18/2014)... (Seattle, WA April 18, 2014) Benaroya Research ... to research how blocking a particular molecule in metastatic ... and the number of lung metastases. BRI scientists have ... protein can shrink tumors by 60 - 80 percent ... to the lung. The $1.8 million five-year grant comes ...
(Date:4/18/2014)... scientists could lead to potential new treatments for breaking ... , Fibrosis, or scarring, is a hallmark of ... lungs can lead to serious organ damage and, in ... options centers on findings made by Swati Bhattacharyya, PhD, ... that a specific protein plays in promoting fibrosis. ...
(Date:4/17/2014)... relief targets that could be used to provide ... College London made the discovery when researching how ... the body. , Dr Marzia Malcangio said: "We ... generation and our findings could help chemotherapy patients ... potential side effect of some chemotherapy drugs (such ...
(Date:4/17/2014)... the University of California, San Diego School of Medicine ... have suffered a recent major loss are more likely ... , The study is published in this month,s issue ... , Because compassionate behaviors are associated with better health ... insights into ways to improve the outcomes of individuals ...
Breaking Medicine News(10 mins):Health News:Religious music brings benefit to seniors' mental health 2Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New clues on tissue scarring in scleroderma 2Health News:New pain relief targets discovered 2Health News:The ilk of human kindness 2
... researchers at Mayo Clinic shows that obese patients with ... loss drug sibutramine, while others who lack these genetic ... are published in the October issue of Gastroenterology ... placebo-controlled study, Mayo researchers measured the impact of two ...
... who are part of an Asian-white ,couple face an ... in which both partners are white, according to a new ... University ,School of Medicine. , The researchers also found ... likely than white women with Asian or white partners to ...
... to help save more than 1 million children, Stores ... N.J., Sept. 30 Quarters found in the,bottom of purses, ... living and dying for needy children. The Vitamin Shoppe is ... save the life of a,child., Affecting up to 140 ...
... Turns to Medical Professional to Apply Rigors,of "Evidence-Based Medicine" ... Give Bad Advice About the Best Medicine For Portfolios?, ... expected to base their diagnoses on what the latest ... specific diseases and other,illnesses. Yet most financial advisors do ...
... Hits $178 Million Mark, WHITE PLAINS, N.Y., Sept. ... it has awarded a new Marshall A. Lichtman,Specialized Center ... Becker Professor of Medicine at Stanford University., Dr. ... year for five,years, for a total of $6.25 million. ...
... presidential debate history, a female nominee will take the stage ... new ground in 1984, it has taken 24 years for ... party ticket. On Thursday night, the nation will be watching ... in the vice presidential debate. A revealing study by a ...
Cached Medicine News:Health News:Genes affect weight loss drug effectiveness 2Health News:Asian-white couples face distinct pregnancy risks, Stanford/Packard 2Health News:Asian-white couples face distinct pregnancy risks, Stanford/Packard 3Health News:Spare Change Can Help Save the Life of a Child 2Health News:Spare Change Can Help Save the Life of a Child 3Health News:Evidence-Based Investing: M.D. Turned Financial Advisor Diagnoses What Ails Most Investors 2Health News:Evidence-Based Investing: M.D. Turned Financial Advisor Diagnoses What Ails Most Investors 3Health News:Evidence-Based Investing: M.D. Turned Financial Advisor Diagnoses What Ails Most Investors 4Health News:Evidence-Based Investing: M.D. Turned Financial Advisor Diagnoses What Ails Most Investors 5Health News:The Leukemia & Lymphoma Society Awards Major Grant to Stanford Researcher 2Health News:Gender is a relative term in politics, MU study finds 2
... MonoPrep LBP Processor is a primary component ... collection, accessioning, processing, sampling, and slide preparation ... management. The MonoPrep LBP Processor produces high-quality ... a broad range of cytology specimen types. ...
... quick and easy automated refill system ... space on your laboratory bench and ... easy-to-use, one-hand system, you only need ... of Diamond Tips. All sizes of ...
200 L, Racked, Pre-sterilized, 96 tips/rack, clear Recommended for 20, 25, 50, 100 and 200 L pipettes. Can also be used with 300 L pipettes when pipetting 200 L or less....
MBP's equivalent to the "Universal Yellow" tip, this 200 L tip utilizes a MicroPoint design for accurate sample handling. 10 L Ref. mark....
Medicine Products: